

## **NEWS RELEASE**

## Hinge Health Announces Pricing of Initial Public Offering

## 2025-05-21

SAN FRANCISCO--(BUSINESS WIRE)-- Hinge Health today announced the pricing of its initial public offering of an aggregate 13,666,000 shares of its Class A common stock, 8,522,528 of which are being sold by Hinge Health and 5,143,472 of which are being sold by certain selling stockholders (the "Selling Stockholders"), at a public offering price of \$32.00 per share. In addition, the Selling Stockholders have granted the underwriters a 30-day option to purchase up to an additional 2,049,900 shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the New York Stock Exchange on May 22, 2025, under the ticker symbol "HNGE." The offering is expected to close on May 23, 2025, subject to customary closing conditions.

Hinge Health intends to use substantially all of its net proceeds from this offering to satisfy tax withholding and remittance obligations related to the net issuance of shares of its Class A and Class B common stock in connection with the vesting and settlement of certain restricted stock units and performance-based restricted stock units. Hinge Health will not receive any proceeds from any sale of shares by the Selling Stockholders.

Morgan Stanley, Barclays and BofA Securities are acting as lead book-running managers for the proposed offering. Evercore ISI, RBC Capital Markets, Truist Securities, Stifel, William Blair, Piper Sandler, Canaccord Genuity, KeyBanc Capital Markets, Needham & Company, Raymond James, and KKR Capital Markets LLC are also acting as book-running managers for the offering.

A registration statement relating to these securities has been filed with and declared effective by the Securities and

Exchange Commission. This offering is being made only by means of a prospectus, copies of which may be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street,

2nd Floor, New York, New York 10014, or email: prospectus@morganstanley.com; Barclays Capital Inc., c/o

Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email:

barclaysprospectus@broadridge.com, or by telephone: (888) 603-5847; or BofA Securities, Inc., NC1-022-02-25,

201 North Tryon Street, Charlotte, North Carolina 28255-0001, Attention: Prospectus Department, by email:

dg.prospectus requests@bofa.com, or by telephone: (800) 294-1322.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall

there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be

unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Hinge Health

Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an

outstanding member experience, improved member outcomes, and cost reductions for its clients. The company

has designed its platform to address a broad spectrum of MSK care—from acute injury, to chronic pain, to post-

surgical rehabilitation—and the platform can help to ease members' pain, improve their function, and reduce their

need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions

from anywhere. The company is headquartered in San Francisco, California.

Media Contact: media@hingehealth.com

Investor Relations Contact: ir@hingehealth.com

Source: Hinge Health

2